To secure a successful product in today's era of cost containment, manufacturers and developers of new in vitro diagnostic technologies must consider payment issuescoverage and reimbursement by healthcare insurers-as critical market forces that must be addressed in the busi-. ness plan. Similar to the regulatory hurdles involving 5lO(k)s and premarket applications, the requirements for payment are related to the unique features of the technology, its costs, and its effect on clinical outcomes. Because cost containment continues to be a driving force for change in healthcare, the business plan must not only include strategies for optimal payment at the product's introduction, but also contain provisions for continuous monitoring of the payment environment throughout the product's life cycle.
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coverage Innovation is the hallmark of the in vitro diagnosticindustry-an industry that includes developers and manufacturers of clinical laboratory tests. In most cases, innovative products have met with few obstacles, with the clearance or approval process of the US Food and Drug Administration (FDA) serving as the primary hurdle and the implementation of a successful marketing campaign as another.' Today's revolution in technologies has challenged the FDA to review its processes to adapt to new levels of analytical sophistication; in response, changes are being made. In the area of sales and marketing, however, a new gatekeeper has emerged in response to the efforts by federal and private sector healthcare insurers (payers) to contain costs. As a result, innovators face new demands to demonstrate the value of theirproduct to healthcare in addition to its safety and effectiveness. To ensure success, manufacturers now must assess the product's value to healthcare at the feasibility phase of develop- 
THE VALUE STORY
Defining healthcarevalue is hardly an exact science. In general, the value of an in vitrodiagnostic test is based on its accuracy, reproducibility, and conditions for use. These qualities may be considered intermediate to the overall value of the test, which includes the associated costs of obtaining a test result balanced with the health consequences to the patient as a result of having the test performed. More simply stated, the value is the sum of costs plus health consequences (outcomes). Costs must include all aspects of testing, including kit costs, personnel and overhead, repeat testing, standards or calibrators, and controls. In this equation, high costs will tend to bring value down, whereas low costs may help to improve value.Outcomes must consider what happens to the patient's health as a result of being tested. For example, if according to an established treatment protocol the test results are an indication for further medical intervention, the patient may have improved health outcomes for having prevented further disease. Conversely, the patient may have poor health outcomes if misdiagnosis leads to unnecessary procedures and potential morbidity. As with costs, good or poor outcomes will tend to influence the value equation with an additive or subtractive effect.
The balancing of costs and outcomes is the primary determinant of value. Some tests may have low costs and high outcomes, making the value quite high. Other tests may have high cost and poor outcomes, resulting in an undesirable low value. Most tests will fall into a middle area, where costs and outcomes are counterbalanced.
For example, a test's high outcomes may be seen as so desirable that concern about its high costs (a subtractive factor) is minimized. Or a test's costs and outcomes may be low except for a narrow patient population for whom itimproves outcomes.
Using the value assessment, the manufacturer has the opportunity to determine whether product enhancements are needed. For example, the product design may require modification of its projected clinical sensitivity and specificity to ensure a higher product value, or the marketing plans may need to be refocused on selected diseases or patient populations. Later, the value story should be reassessed by using the data generated during the clinical trial. Using thislargerdatabasewill help provide a more accurateestimateof the product'svalue.
Although payers are increasingly requiring justification for coverage of new technologies,a value story is not always required.In general, a test's value would not be critical when it isobvious thatthe cost of testing and the patient's healthare not negativelyaffected. For example, if a product is shown to be substantially equivalentto an existingproduct and the cost of testing is less than that of the predicate device,the value is simply that of minimizing cost. For other situations, several questions may help determine the need for a value story: 1) Does ithave uncertainhealth outcomes? A new technology may effect changes in medical practicewithout first establishing a long-term health benefit. This would also apply to established technology that has been tested for a new intended use.
2) Is its use controversial? The medical community and those in allied healthcare fields are using more sophisticated means of designing investigations and analyzing clinical data, often with conflicting conclusions. This may place the payer's coverage decisions on hold, which will further delay use of the technology.
3) Does it increase costs over current practice? That is, is use of the new technology more expensive than the diagnostic method thatisbeing replaced? Any testor procedure that will increase costs will require justification for payers to provide coverage and offerreasonablereimbursement.
4) Is it subject to high utilization? All payers review the frequency of use for any covered product or procedure.Ifit is anticipated that a product or procedure will be used or isbeing used more frequentlythan expected, the cost and healthbenefits must be established.2 Any new product or medical procedure that meets any of these criteria has a high probability of needing a value storyto obtain coverage.
INCLUDE PAYMENT
STRATEGIES IN THE BUSINESS
PLAN
Because today'sin vitrodiagnostic market isincreasingly dependent on the coverage offered by payers and, as an ancillary, coverage at an optimal reimbursement amount, payment planning must become part of the business plan. Without a payment strategy, even the most innovative and relevant of technologies will have a diminished market introduction because of the lack of coverage and adequate reimbursement for potential customers. Although this is not the primary determinant of a successful product introduction, addressing these payment activities in the business plan will help to ensure a stronger market entry with a shorter time before coverage is offered and sales begin.
EARLY ASSESSMENT OF PAYMENT ENVIRONMENT
At the feasibility phase of development, the payment environment as well as the targeted market should be evaluated. Cost may change at any time from the feasibility phase to market entry, it is important to schedule future assessments at meaningful time points to ensure that the same conditions are in effect.
INCLUDE ECONOMIC QUESTIONS IN THE CLINICAL TRIAL
DESIGN
For thosetechnologiesneeding an economic justification aspart of the value story, the clinical trialdesign should address associatedcosts as well as clinical sensitivity and specificity. Following treatment pathways established by the clinical investigators, developers should determine the cost per test result and the cost of any medical intervention that is undertaken because of the test result. This determination should also include such direct costs as the cost of adverse reactions after a false-positive or false-negative test result. It may be necessary to obtain similar costsfora competitive product or procedure. Depending on the economic and health benefit analysisto be performed, the treatment pathways may require modification and possible consideration of comparative testing. Consultation with healthcare economists who perform cost-effectiveness analysis is recommended. For some products, e.g., those that may lead to invasive procedures or that diagnose predisposition to lifethreatening or life-debilitating diseases, it may be appropriate to assessthe patient's quality of life relevant to having the test performed. For these investigations, preexisting questionnaires may be qualified and incorporated into the clinical trial protocol.
REGULATORY CONSIDERATIONS
The type of FDA submission,510(k)forsubstantial equivalence or PMA for premarket application approval, may have implications for the amount that payers will reimburse for the new product. The 510(k) submission is the faster regulatory route to market introduction, but its use impliesequivalence to a predicate device. Because payers do consider FDA decisions in their coverage reviews, the new product will be covered. However, the reimbursement will be at the same amount as for the predicate device-even if the new product is more accurate, faster, adaptable to multiple settings, and probably improves patient health outcomes.
Therefore, selection of a predicate device should receive careful consideration.
PMAs, which represent new technologies and old technologies with new intended uses, do not have reimbursement amounts set equivalent to a predicate device. For PMA products, the manufacturer has an opportunity to meet with the payer and propose reimbursement amounts based on the product pricing and other information.
Regardless of the regulatory route selected, payersdo relyon peer-reviewedpublications of clinical studiesin theircoverage decisions, so itisadvisablefor developers to publishearlyand often.
PARTNERSHIPS
Just as partnering with the clinical investigators is key to a successfultrial, forming partnershipswith conceptual leaders withinthe medical community can be key to obtaining coverage. As managed care organizations increase in number and enrollment, they are increasingly seen as role models for coverage decisions by other payers. As such, these organizations should be considered as clinical trial sites or potential marketing study sites. In this approach, it is wise to meet with the managed care medical and policy staff to determine their criteria for coverage of new products or procedures. This meeting should occur well in advance of the clinical trial, to ensure that the study design will include all of the required protocols. Medical directors of the nation's biggest payer, Medicare, and of other payer groups may be valuable partners, as might be renowned members of medical specialty groups. Moreover, although educating potential partners on the technology is critical, the manufacturer/marketer must also have a clear vision of the potential healthcare benefits to be realized. Having enlisted the interest of potential partners early in the project's development will help to promote their support of the clinical trial's conclusions and any health benefits determined.
MONITOR
COVERAGE POLICY DEVELOPMENT
One of the attemptsto controlmedical costsisthe development of medical guidelines. the settingfor use,fivebasicitems should be included in every value story: (a) a summary of the current medical practice with references to any existing medical guidelines; (b) a summary of the product's safety and effectiveness; (c) a copy of the product's FDA clearance or approval letter; (d) copies of all publications describing the new technology and its applications; and (e) an assessment of the technology's health benefits and costs in the form of an economic or actuarial model. As a powerful marketing tool, the final value storymust be clear, concise, and flexible so that it can be adapted to the needs of different payers.
In summary, today's emphasis on containing healthcare costs willfavor those manufacturers who address payment issues in theirbusinessplan. Considering the followingfour stepswill help ensure a successful product introduction: First, assess the payment environment earlyand throughout the product development continuum. Second, ensure that the clinical trial design includes the appropriate measures for economic data. Third, identify key partners who would support and promote the new technologies. And fourth, monitor the agencies, payers, and specialty groups for new trends in coverage decisions. With a clear value story, in vitro diagnostic manufacturers and developers can join the new gatekeepers in the payment revolution and succeed in bringing new technologies to the market.
